Switch theme
Sign up to access all valuation multiples
Shanghai Allist Pharmaceuticals Co Ltd is an innovative drug company in the field of cancer treatment.
2004
n/a
LTM Revenue $527M
LTM EBITDA $224M
$5.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Shanghai Allist has a last 12-month revenue of $527M and a last 12-month EBITDA of $224M.
In the most recent fiscal year, Shanghai Allist achieved revenue of $278M and an EBITDA of $95.9M.
Shanghai Allist expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shanghai Allist valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $278M | $489M | XXX | XXX | XXX |
| Gross Profit | $72.3M | $105M | XXX | XXX | XXX |
| Gross Margin | 26% | 21% | XXX | XXX | XXX |
| EBITDA | $95.9M | $212M | XXX | XXX | XXX |
| EBITDA Margin | 34% | 43% | XXX | XXX | XXX |
| Net Profit | $2.5M | $18.0M | XXX | XXX | XXX |
| Net Margin | 1% | 4% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Shanghai Allist's stock price is CNY 88 (or $12).
Shanghai Allist has current market cap of CNY 39.5B (or $5.4B), and EV of CNY 36.5B (or $5.0B).
See Shanghai Allist trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.0B | $5.4B | XXX | XXX | XXX | XXX | $0.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Shanghai Allist has market cap of $5.4B and EV of $5.0B.
Shanghai Allist's trades at 9.5x LTM EV/Revenue multiple, and 22.4x LTM EBITDA.
Analysts estimate Shanghai Allist's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Shanghai Allist and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.0B | XXX | XXX | XXX |
| EV/Revenue | 10.3x | XXX | XXX | XXX |
| EV/EBITDA | 23.7x | XXX | XXX | XXX |
| P/E | 28.0x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpShanghai Allist's NTM/LTM revenue growth is 25%
Shanghai Allist's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Shanghai Allist's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Shanghai Allist's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Shanghai Allist and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 76% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 121% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 69% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 30% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 68% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shanghai Allist acquired XXX companies to date.
Last acquisition by Shanghai Allist was XXXXXXXX, XXXXX XXXXX XXXXXX . Shanghai Allist acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Shanghai Allist founded? | Shanghai Allist was founded in 2004. |
| Where is Shanghai Allist headquartered? | Shanghai Allist is headquartered in China. |
| Is Shanghai Allist publicy listed? | Yes, Shanghai Allist is a public company listed on SHG. |
| What is the stock symbol of Shanghai Allist? | Shanghai Allist trades under 688578 ticker. |
| When did Shanghai Allist go public? | Shanghai Allist went public in 2020. |
| Who are competitors of Shanghai Allist? | Similar companies to Shanghai Allist include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Shanghai Allist? | Shanghai Allist's current market cap is $5.4B |
| What is the current revenue of Shanghai Allist? | Shanghai Allist's last 12-month revenue is $527M. |
| What is the current EBITDA of Shanghai Allist? | Shanghai Allist's last 12-month EBITDA is $224M. |
| What is the current EV/Revenue multiple of Shanghai Allist? | Current revenue multiple of Shanghai Allist is 9.5x. |
| What is the current EV/EBITDA multiple of Shanghai Allist? | Current EBITDA multiple of Shanghai Allist is 22.4x. |
| What is the current revenue growth of Shanghai Allist? | Shanghai Allist revenue growth between 2023 and 2024 was 76%. |
| Is Shanghai Allist profitable? | Yes, Shanghai Allist is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
